Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.17954
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Risankizumab Versus Ustekinumab for Plaque Psoriasis: A Critical Appraisal

British Journal of Dermatology
DermatologyMedicine
2019English

Risankizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber
Pharmacology
2019English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

Meta‐analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient

Drug Safety - Case Reports
Pharmacology
2017English

Psoriatic Skin Molecular and Histopathological Profiles Following Treatment With Risankizumab Versus Ustekinumab

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Psoriasis: Therapie Mit Ustekinumab Ist Langzeitig Erfolgreich

hautnah dermatologie
2013English

Infliximab for the Treatment of Plaque Psoriasis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Dimethyl Fumarate for the Treatment of Plaque Psoriasis

Prescriber
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy